IRCCS SAN RAFFAELE ROMA SRL

Their core work

IRCCS San Raffaele Roma is an Italian clinical research institute (IRCCS — Istituto di Ricovero e Cura a Carattere Scientifico) recognized by the Italian Ministry of Health as a center of excellence in biomedical research. Their scientific work spans oncology and neurology, with a strong computational thread running through both: they build predictive models, computational frameworks, and AI-based decision support systems applied to real clinical problems. In the REVERT project they led research into targeted combinatorial therapies for unresectable colorectal cancer, combining molecular biology with machine learning to model cancer progression. In AI-Mind they contribute to multimodal AI screening tools for early dementia detection, working with brain connectivity data and deep learning pipelines.

What they specialise in

How they've shifted over time

Their H2020 entry in 2020 was anchored in oncology: molecular mechanisms of colorectal cancer, combinatorial drug therapy, and building computational frameworks to predict cancer progression — with AI as a supporting tool for therapy decisions. By 2021, their second project shifted disease domain entirely to neurology, with AI and deep learning becoming the primary focus rather than a support role. The trajectory is clear: from disease-specific clinical research with computational elements, toward AI methodology as a horizontal capability applicable across disease areas.

They are positioning themselves as a clinical AI institute — capable of applying machine learning and deep learning to diverse disease areas — rather than remaining specialists in any single pathology.

How they like to work

They are comfortable in both leadership and partner roles: they coordinated REVERT (a 4-year RIA) and joined AI-Mind as a participant, suggesting flexibility depending on where their specific expertise fits. With 42 unique partners across just 2 projects, they work in large multi-stakeholder consortia typical of RIA grants, not in tight bilateral arrangements. This indicates experience navigating complex consortium governance and an openness to contributing as a specialist node within bigger European collaborations.

42 unique consortium partners across 11 countries from only 2 projects points to participation in large, geographically diverse RIA consortia — likely spanning southern and northern Europe. No evidence of repeated partnerships, suggesting they prioritize breadth of collaboration over deep bilateral ties.

What sets them apart

As an IRCCS-designated institute, San Raffaele Roma operates at the intersection of hospital-grade clinical practice and academic-level biomedical research — a combination that many pure universities or pure companies cannot offer. Their ability to contribute both clinical domain knowledge (real patient data, treatment protocols) and computational modelling capacity makes them a credible bridge between bench science and clinical deployment. For a consortium needing a clinical validation partner in Italy with AI credentials, they fill a specific gap.

Highlights from their portfolio

• REVERT
  Their largest project by funding (EUR 998k) and only coordinator role — a 4-year RIA targeting one of oncology's hardest problems, unresectable colorectal cancer, using a combination of molecular research and AI decision support.
• AI-Mind
  A high-profile pan-European AI project on dementia screening running to 2026, demonstrating their ability to join top-tier consortia as a specialist contributor in brain connectivity and multimodal risk assessment.